Results 101 to 110 of about 2,413 (124)

Astrocyte Functional Heterogeneity in Multiple Sclerosis. [PDF]

J Clin Neurol
Hong S, Kim KG, Quintana FJ, Lee HG.
europepmc   +1 more source

Sema4D Knockout Attenuates Choroidal Neovascularization by Inhibiting M2 Macrophage Polarization Via Regulation of the RhoA/ROCK Pathway. [PDF]

Invest Ophthalmol Vis Sci
Cui K, Tang X, Yang B, Fan M, Hu A, Wu P, Yang F, Lin J, Kong H, Lu X, Yu S, Xu Y, Liang X.   +12 more
europepmc   +1 more source

A multi-omics approach combining causal inference and <i>in vivo</i> validation identifies key protein drivers of alcohol-associated liver disease. [PDF]

Front Immunol
Zhou Q, Ma X, Cui Q, Zhang L, Yao C, Zhang Z, Wang X, Chu L.   +7 more
europepmc   +1 more source

Proteomic Signatures of Cardiac Dysfunction Among People With Diabetes: The Atherosclerosis Risk in Communities Study. [PDF]

Circ Heart Fail
Echouffo-Tcheugui JB, Ndumele CE, Chen J, Rooney MR, Walker KA, Schlosser P, Matsushita K, Grams ME, Ballantyne CC, Hoogeveen RC, Boerwinkle E, Yu B, Shah AM, Dubin RF, Deo R, Ren Y, Rotter JI, Taylor KD, Post WS, Ganz P, Selvin E, Coresh J.   +21 more
europepmc   +1 more source

Potential drug targets for ovarian cancer identified through Mendelian randomization and colocalization analysis. [PDF]

J Ovarian Res
Liu S, Lin H, Zhang K, Zhou Q, Shen Y.
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Sema4D as a biomarker for Predicting rheumatoid arthritis disease activity

Clinical Rheumatology, 2023
Lingyu Fu, Zhang Yuelin, Liu Huiyuan
exaly  

Soluble Sema4D in Plasma of Head and Neck Squamous Cell Carcinoma Patients Is Associated With Underlying Non-Inflamed Tumor Profile

Frontiers in Immunology, 2021
Ioana Ghita, Rania Younis, Risa Chaisuparat   +2 more
exaly  

Upregulation of IFN-β induced by Sema4D-dependent partial Erk1/2 inhibition promotes NO production in microglia

Biochemical and Biophysical Research Communications, 2020
Tatsuo Furuyama, Shinobu Inagaki, Toshinori Sawano   +2 more
exaly